

**07:20 Registration & Breakfast**

**08:10 Welcome Speech by Leonard Sachs, Managing Director, Sachs Associates - Ballroom AB**

**08:15 "Oncology within the Context of the Changing Reimbursement Landscape" by Roger Longman, CEO, Real Endpoints - Ballroom AB**

**Industry Roundtable: "The Changing Landscape of Regulation, Reimbursement & Pricing Under the New Administration" - Ballroom AB**

*Chaired by:*

Roger Longman, CEO, Real Endpoints

*Panelists:*

**08:30** Julie Locklear, Vice President & Head, Health Economics & Outcomes Research, EMD Serono, Inc.

Peter Thompson, Private Equity Partner, OrbiMed Advisors, LLC

Rena Conti, Assistant Professor Hematology/Oncology, Department of Pediatrics, The University of Chicago

Sachin Kamal-Bahl, Vice President and Head, Innovation Center, Patient & Health Impact, Pfizer, Inc.

**Current Trends in Pharma-Biotech Deal Making Panel - Ballroom AB**

*Co-Chaired by:*

Mike Rice, Principal, Defined Health, a Cello Health Business

Peter Sandor, VP, Oncology Therapeutic Area Head for Marketing Strategy, Astellas Pharma US, Inc.

*Panelists:*

**09:00** Chris DeRespino, Director, Business Development, Amgen, Inc.

Guillaume Vignon, Head of Immuno-Oncology Licensing & Business Development, EMD Serono, Inc.

Ji Li, Global Head of Business Development, BeiGene

Michael Margolis, Co-Head of Healthcare Investment Banking, Oppenheimer & Co., Inc.

Stephen Sands, BD&L Director Oncology/Immunology, F. Hoffmann-La Roche Ltd.

Timothy Herpin, VP, Head of Transactions (UK), Business Development, AstraZeneca

**09:50 Coffee Break**

**New Approaches to IO & Combination Therapies Panel - Ballroom AB**

*Co-Chaired by:*

James Mulé, Associate Center Director for Translational Research, Moffitt Cancer Center

Paul Rennert, President & CSO, Aleta Biotherapeutics

*Panelists:*

**10:00** John Beadle, CEO, PsiOxus Therapeutics Ltd.

Juergen Gamer, VP Business Development, Apogenix AG

Lindy Durrant, CSO, Scancell Limited

Lisa Decker, Executive Director, Business Development, Nektar Therapeutics

Loic Vincent, Head, Immunology Partnerships, Takeda Pharmaceuticals

Patrick Tricoli, CEO, Nanobiotix Corp.

Presenting Companies **Track A - Ballroom C**  
Moderated by: **Raghuram Selvaraju**, H.C. Wainwright & Co., LLC

**10:10** BerGenBio ASA - [BGBIO:NO]

**10:30** Oncology Venture - [OV:SS]

**10:50** Helix Biopharma Corp. - [TSE:HBP]

**11:10** Immunicum AB - [IMMU:SS]

**11:30** Scancell Limited - [LON: SCLP]

**11:50** PsiOxus Therapeutics Ltd.

**12:10** Nouscom AG

**12:20** PeptiMed, Inc.

Presenting Companies **Track B - Ballroom AB**  
Moderated by: **Robin Davison**, New Science Global Healthcare Fund

**10:50** BioLineRx Ltd. - [NASDAQ:BLRX]

**11:10** Nanobiotix Corp.- [EPA:NANO]

**11:30** OSE Immunotherapeutics - [EPA:OSE]

**11:50** eTheRNA immunotherapies NV

**12:10** RXi Pharmaceuticals, Corp. - [NASDAQ:RXII]

**12:20** Mikro Biosistemler, Inc.

**12:30 Networking Lunch**

**12:30 Networking Lunch**

**13:20 "Perspectives on Cell Therapies" by Samuele Butera, Global Cell & Gene Therapies Business Leader, Novartis Oncology**

**Latest Perspectives on Cell & Gene Therapies Panel - Ballroom AB**  
*Co-Chaired by:*  
Axel Hoos, SVP, TA Head, Oncology R&D, GSK  
Gregory Frost, CEO and Chairman, F1BioVentures  
*Panelists:*  
**13:40** Aaron Foster, VP of Product Discovery, Bellicum Pharmaceuticals, Inc.  
Debra Bowes, EVP, Business and Strategic Development, MaxCyte, Inc.  
Gregory Naeve, Head External R&D Innovation, ImmunoOncology & Rinat Labs, San Francisco, Oncology, Pfizer, Inc.  
Helen Tayton-Martin, CBO, Adaptimmune Therapeutics  
Samuele Butera, Global Cell & Gene Therapies Business Leader, Novartis Oncology

Presenting Companies **Track C - Ballroom C**  
Moderated by: **Brad Loncar**, Loncar Investments

**13:40** Mitra Biotech, Inc.

**14:00** Apogenix AG

**14:20** MOLOGEN AG - [ETR: MGN]

**Technology & Innovation Panel - Ballroom AB**  
*Co-Chaired by:*  
Howard Fingert, Senior Medical Director for Clinical Intelligence, Takeda Pharmaceuticals  
Rahul Jasuja, CEO & Board Member, Pelican Therapeutics  
*Panelists:*  
**14:40** Ferran Prat, VP, Strategic Industry Ventures, MD Anderson Cancer Center  
Francis Kern, Senior Director of External Scientific Affairs, Daiichi Sankyo  
Gary Sclar, VP, Dana-Farber Innovations, Dana-Farber Cancer Institute  
Lee Greenberger, SVP and CSO, The Leukemia & Lymphoma Society

Presenting Companies **Track D - Ballroom C**  
Moderated by: **Kumaraguru Raja**, Noble Life Science Partners

**14:50** IO Biotech ApS

**15:00** eFFECTOR Therapeutics, Inc.

**15:10** 7 Hills Pharma, LLC

**15:20** Venn Therapeutics, LLC

**15:30** VLP Therapeutics

**15:40** Icell Kealex Therapeutics

**15:50** Exactis Innovation

Presenting Companies **Track E - Ballroom AB**  
Moderated by: **Juan Pedro Serrate**, Edison Investment Research

**15:20** Adaptimmune Therapeutics - [NASDAQ:ADAP]

**15:40** MaxCyte, Inc. - [LON:MXCT]

**16:00 Coffee Break**

**China-US DealMaking Panel - Ballroom AB**  
*Introductory Overview by:*  
Helen Chen, Managing Director and Head of China Life Sciences, L.E.K. Consulting Limited  
*Chaired by:*  
Ji Li, Global Head of Business Development, BeiGene  
*Panelists:*  
**16:10** Helen Chen, Managing Director and Head of China Life Sciences, L.E.K. Consulting Limited  
Hongbo Lu, Partner, Lilly Asian Ventures  
Ian Woo, Managing Director, Healthcare Banking, Lazard  
Walter Lau, Managing Partner, Cenova Venture  
Weimin Tang, Executive Director, Business Development, Jiangsu Hengrui Medicine Co.  
Yuwen Liu, Founding Partner, BoHe Angel Fund

Presenting Companies **Track F - Ballroom C**  
Moderated by: **Jacob Plieth**, EP Vantage

**16:10** Singh Biotechnology, LLC

**16:30** AIMM Therapeutics BV

**Investor Roundtable - Ballroom AB**  
*Co-Chaired by:*  
Boris Peaker, Managing Partner, Biotechnology Equity Research, Cowen and Company  
Kuldeep Neote, Senior Director, New Ventures, J&J Innovation Center-Boston  
*Panelists:*  
**17:10** Bard Geesaman, Managing Director, MPM Capital  
Brad Loncar, CEO, Loncar Investments  
David Malek, Chief Business Officer, BioLineRx Ltd.  
Joseph Sum, Director of Research, EcoR1 Capital, LLC  
Thilo Schroeder, Partner, Nextech Invest Ltd.

**18:00 Networking Reception**

**19:00 End of the 3rd IOBDLI Forum**